Moderna Inc (NASDAQ:MRNA) CEO Stephane Bancel sold 9,000 shares of the business’s stock in a transaction dated Wednesday, July 29th. The shares were sold at an average price of $82.00, for a total value of $738,000.00. Following the completion of the sale, the chief executive officer now directly owns 6,684,858 shares of the company’s stock, valued at $548,158,356. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Stephane Bancel also recently made the following trade(s):

  • On Friday, July 24th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $71.56, for a total value of $790,451.76.
  • On Wednesday, July 22nd, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $79.61, for a total value of $716,490.00.
  • On Monday, July 20th, Stephane Bancel sold 6,326 shares of Moderna stock. The shares were sold at an average price of $83.53, for a total value of $528,410.78.
  • On Thursday, July 16th, Stephane Bancel sold 19,000 shares of Moderna stock. The shares were sold at an average price of $83.92, for a total value of $1,594,480.00.
  • On Thursday, July 9th, Stephane Bancel sold 10,000 shares of Moderna stock. The shares were sold at an average price of $62.04, for a total value of $620,400.00.
  • On Monday, July 6th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $59.53, for a total value of $657,568.38.
  • On Wednesday, July 1st, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $62.92, for a total value of $566,280.00.
  • On Friday, June 26th, Stephane Bancel sold 11,046 shares of Moderna stock. The shares were sold at an average price of $60.65, for a total value of $669,939.90.
  • On Wednesday, June 24th, Stephane Bancel sold 9,000 shares of Moderna stock. The shares were sold at an average price of $63.25, for a total value of $569,250.00.
  • On Monday, June 22nd, Stephane Bancel sold 4,521 shares of Moderna stock. The shares were sold at an average price of $65.92, for a total value of $298,024.32.

MRNA opened at $74.10 on Friday. The stock’s 50 day simple moving average is $69.03 and its 200 day simple moving average is $44.88. Moderna Inc has a 1-year low of $11.54 and a 1-year high of $95.21.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.02. The business had revenue of $8.39 million for the quarter, compared to analysts’ expectations of $18.17 million. Moderna had a negative return on equity of 37.49% and a negative net margin of 963.84%. As a group, equities research analysts forecast that Moderna Inc will post -1.41 earnings per share for the current fiscal year.

MRNA has been the subject of several analyst reports. Argus initiated coverage on Moderna in a research note on Tuesday, June 30th. They set a “buy” rating and a $80.00 price objective for the company. Piper Sandler upped their price objective on Moderna from $100.00 to $134.00 in a research note on Wednesday, July 15th. JPMorgan Chase & Co. downgraded Moderna from an “overweight” rating to a “neutral” rating and increased their target price for the stock from $60.00 to $89.00 in a research note on Monday, July 20th. They noted that the move was a valuation call. Bank of America cut their target price on Moderna from $80.00 to $75.00 in a research note on Wednesday, June 3rd. Finally, Zacks Investment Research raised Moderna from a “hold” rating to a “buy” rating and set a $86.00 target price for the company in a research note on Tuesday, July 21st. Four analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $88.78.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Corbenic Partners LLC acquired a new stake in shares of Moderna in the 2nd quarter worth approximately $32,000. Weaver Consulting Group acquired a new stake in Moderna during the 2nd quarter valued at $48,000. D Orazio & Associates Inc. acquired a new stake in Moderna during the 2nd quarter valued at $51,000. Creative Financial Designs Inc. ADV acquired a new stake in Moderna during the 2nd quarter valued at $64,000. Finally, CVA Family Office LLC grew its holdings in Moderna by 40.0% during the 2nd quarter. CVA Family Office LLC now owns 1,400 shares of the company’s stock valued at $90,000 after buying an additional 400 shares during the last quarter. Institutional investors and hedge funds own 52.09% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

See Also: What is the Euro STOXX 50 Index?

Insider Buying and Selling by Quarter for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.